期刊
CHEMMEDCHEM
卷 10, 期 10, 页码 1635-1640出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/cmdc.201500287
关键词
cancer; cyclooxygenases; drug design; positron emission tomography; radiochemistry
资金
- Dianne and Irving Kipnes Foundation (Canada)
- Canadian Institute for Health Research (CIHR)
- National Science and Engineering Research Council of Canada (NSERC)
- Alberta Cancer Foundation (ACF)
A series of novel fluorine-containing cyclooxygenase-2 (COX-2) inhibitors was designed and synthesized based on the previously reported fluorescent COX-2 imaging agent celecoxib-NBD (3; NBD=7-nitrobenzofurazan). In vitro COX-1/COX-2 inhibitory data show that N-(4-fluorobenzyl)-4-(5-p-tolyl-3-trifluoromethylpyrazol-1-yl)benzenesulfonamide (5; IC50=0.36M, SI>277) and N-fluoromethyl-4-(5-p-tolyl-3-trifluoromethylpyrazol-1-yl)benzenesulfonamide (6; IC50=0.24M, SI>416) are potent and selective COX-2 inhibitors. Compound 5 was selected for radiolabeling with the short-lived positron emitter fluorine-18 (F-18) and evaluated as a positron emission tomography (PET) imaging agent. Radiotracer [F-18]5 was analyzed in vitro and in vivo using human colorectal cancer model HCA-7. Although radiotracer uptake into COX-2-expressing HCA-7 cells was high, no evidence for COX-2-specific binding was found. Radiotracer uptake into HCA-7 tumors in vivo was low and similar to that of muscle, used as reference tissue.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据